

to a collection of information unless it displays a valid OMB control number.

(use as many sheets as necessary)

Attorney Docket Number	UBC.P-031
------------------------	-----------

2

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/605,498
Filing Date	10/2/2003
First Named Inventor	Gleave et al.
Art Unit	1141/005
Examiner Name	Bowman
Attorney Docket Number	UBC-P-031

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AMB		BUBENDORF ET AL., Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays, Journal of the National Cancer Institute, 10/20/1999, Page(s) 1758-1764, Volume 91, Number 20	
		CORNFORD ET AL., Heat Shock Protein Expression Independently Predicts Clinical Outcome in Prostate Cancer, Cancer Research, 12/15/2000, Page(s) 7099-7105, Volume 60	
		HORMAN ET AL., Anti-Sense Inhibition of Small-Heat-Shock-Protein (HSP27) Expression in MCF-7 Mammary-Carcinoma Cells Induces Their Spontaneous Acquisition of A Secretory Phenotype, Int. J. Cancer, 3/17/1999, Page(s) 574-582, Volume 82	
		OESTERREICH ET AL., The Small Heat Shock Protein hsp27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines, Cancer Research, 10/1/1993, Page(s) 4443-4448, Volume 53	
		RICHARDS ET AL., Effect of Overexpression of the Small Heat Shock Protein HSP27 on the Heat and Drug Sensitivities of Human Testis Tumor Cells, Cancer Research, 5/15/1996, Page(s) 2446-2451, Volume 56	
		RONDEAUX ET AL., Effects of Antisense HSP27 Gene Expression in Osteosarcoma Cells, In Vitro Cell Dev. Biol. - Animal, 10/1/1997, Page(s) 655-658, Volume 33	
		WU ET AL., Expression of the 25-kDa Heat-Shock Protein (HSP27) Correlates with Resistance to the Toxicity of Cadmium Chloride, Mercuric Chloride, cis-Platinum(II)-Diammine Dichloride, or Sodium Arsenite in Mouse Embryonic Stem Cells Transfected with Sense or Antisense HSP27 cDNA, Toxicology and Applied Pharmacology, 7/18/1996, Page(s) 330-339, Volume 141	
		YAMOTO ET AL., Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance, Cancer Letters, 4/2/2001, Page(s) 173-181, Volume 168	


Examiner Signature	AMB	Date Considered	4/28/05
--------------------	-----	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Use as many sheets as necessary)

Complete if Known

Application Number	10/605,498
Filing Date	10/2/2003
First Named Inventor	Gleave et al.
Art Unit	1614 1635
Examiner Name	AMY BOWMAN
Attorney Docket Number	UBC.P-031

Sheet	1	of	2	Attorney Docket Number	UBC.P-031
-------	---	----	---	------------------------	-----------

[illegible][illegible]

Examiner Signature	<i>Att Bowman</i>	Date Considered	4/28/08
-----------------------	-------------------	--------------------	---------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/605,498
		Filing Date	10/2/2003
		First Named Inventor	Gleave et al.
		Art Unit	1014 1085
		Examiner Name	A. Bowman
Sheet 2 of 2	Attorney Docket Number	UBC.P-031	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AHB		DATABASE WPI, Section Ch, Week 199737,1997, Publisher: Derwent Publications Ltd., London, GB, XP002272450	
AHB		GARRIDO ET AL., Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells the Doxorubicin-protecting effect of HSP27, European Journal of Biochemistry, 1996, Page(s) 653-659, Volume 237, Number 3, XP001004835	
AHB		GOTHAM ET AL., Antisense and Sirna Technologies - SMI Conference, IDRUGS, 2003, Page(s) 211-214, Volume 6, Number 3, Publisher: Current Drugs LTD, GB, XP008026723	
AHB		MORINO ET AL., Specific Regulation of HSPs in Human Tumor Cell Lines by Flavonoids, In Vivo - International Journal of In Vivo Research, 1997, Page(s) 265-270, Volume 11, Number 3; XP009007378	
AHB		TAMM ET AL., Antisense therapy in oncology: new hope for an old idea?, Lancet, 2001, Page(s) 489-497, Volume 358, Number 9280, XP004299974	

Examiner Signature	AH Bowman	Date Considered	4/28/05
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.